Why did SPL fall 33.3% on 20 Oct 2026?

SPL

Starpharma · Pharmaceuticals, Biotechnology & Life Sciences

▼ 33.3%at the close on Tue 20 Oct

$10,000 in SPL shares fell to $6,667 that day. It was down as much as 34.7% during the day: about 15 times a usual day's move for SPL, with twice the usual shares traded.

A takeover or merger deal

Starpharma's stock fell sharply after it acquired a 66% majority stake in Petalion, with investors likely reacting negatively to the capital deployment and dilution risk associated with this early-stage FAP-targeted cancer program.

No ETF we cover holds Starpharma.

The news

4 of the 4 articles we read name Starpharma. Headlines link to the publisher.

The other 2 articles ›
How the model got there ›

Multiple news sources published within hours of the price move confirm Starpharma acquired a controlling 66% stake in Petalion, a FAP-targeted cancer bet. The market reaction is consistent with a 'sell the news' or skeptical response to an early-stage biotech acquisition — concerns about capital deployment, dilution, and strategic fit with the DEP platform are typical triggers for sharp sell-offs in small-cap biotechs. The health sector index was actually up ~0.95% on the day and peers were flat, ruling out sector or macro explanations; the move is clearly stock-specific and timed directly with the Petalion deal news. Confidence is medium rather than high because no formal ASX announcement was found in Layer 1 (suggesting the deal may have been announced just outside the window or via a non-routine filing excluded from the search), so the full terms and any capital raise details are not confirmed.

Company announcements

  • Starpharma secures majority ownership of Petalion

    Web Cast · 20 Oct 2026 · market sensitive

All announcements on asx.com.au ↗

Markets that moved with it · 1

Markets that tend to move with this stock, on the same day or the day before.

  • ASX 200 Health CareIts sector · same dayother way+0.95%

How is the site working for you?